Our stock price may be extremely volatile. The trading price of our common stock has been highly volatile. As a result of this volatility; you may not be able to sell your common stock at or above your purchase price; if at all. We believe the trading price of our common stock will remain highly volatile and may fluctuate substantially due to factors such as adverse results or delays in clinical trials announcement of FDA approval or non approval; or delays in the FDA review process; of our or our collaborators product candidates or those of our competitors or actions taken by regulatory agencies with respect to our; our collaborators or our competitors clinical trials 37 TABLE OF CONTENTS announcement of new products by us or our competitors quarterly variations in our or our competitors results of operations; including as a result of recognition of upfront licensing or other fees; the timing and amount of expenses incurred for clinical development; regulatory approval and commercialization of our product candidates litigation; including intellectual property infringement lawsuits; involving us financing transactions developments in the biotechnology and pharmaceutical industries the general performance of the equity markets and in particular the biopharmaceutical sector of the equity markets departures of key personnel or board members developments concerning current or future collaborations FDA or international regulatory actions affecting our industry generally and third party reimbursement policies. This volatility and general market declines in our industry over the past several years have affected the market prices of securities issued by many companies; often for reasons unrelated to their operating performance; and may adversely affect the price of our common stock. In the past; securities class action litigation has often been instituted following periods of volatility in the market price of a company s securities. A securities class action suit against us could result in potential liabilities; substantial costs and the diversion of management s attention and resources; regardless of the outcome of the action.